Gynecological Endocrinology最新文献

{"title":"Clinical value of hsa_circ_0003254 in postmenopausal osteoporosis and its role in the progression of osteoporosis.","authors":"Zhen Chen, Ruiquan Tan, Yong Dai, Yuhao Wen, Cheng Zhong, Danxia Lin, Weibing Chen","doi":"10.1080/09513590.2026.2677988","DOIUrl":"https://doi.org/10.1080/09513590.2026.2677988","url":null,"abstract":"<p><strong>Objective: </strong>Circular RNAs (circRNAs) are important regulators of human disease, yet their specific mechanistic role in postmenopausal osteoporosis (PMOP) remains unclear. This study aimed to investigate the expression pattern, diagnostic value, and biological function of hsa_circ_0003254.</p><p><strong>Methods: </strong>This study enrolled 207 postmenopausal females grouped into osteopenia (OPn, <i>n</i> = 72), osteoporosis (OP, <i>n</i> = 85), and healthy controls (Health, <i>n</i> = 50). RT-qPCR was employed to detect expression differences of hsa_circ_0003254, receiver operating characteristic (ROC) analysis, and logistic regression were utilized to assess its diagnostic value. The functional role of hsa_circ_0003254 in osteogenesis was assessed by transfecting hBMSCs with pcDNA-circ or si-circ. Western blot analysis was performed to determine the protein levels of RUNX2, ALP, and OCN.</p><p><strong>Results: </strong>Analysis of the clinical cohort revealed that the expression of hsa_circ_0003254 was significantly elevated in patients with OPn and OP compared to healthy controls. Its expression level showed a significant positive correlation with both the PINP and the CTX-1. ROC analysis confirmed the diagnostic efficacy of hsa_circ_0003254 for PMOP, distinguishing healthy controls from OP patients (AUC = 0.876) and differentiating OPn from OP patients (AUC = 0.934). Multivariate logistic regression analysis confirmed hsa_circ_0003254 as a risk factor for PMOP (OR = 18.507, <i>p</i> < 0.001). Functionally, Osteogenic induction downregulated hsa_circ_0003254. Overexpression suppressed ALP activity, cell viability, and osteogenic gene expression (ALP, RUNX2, OCN), while knockdown enhanced all these parameters.</p><p><strong>Conclusions: </strong>Hsa_circ_0003254 may serve as a potential circulating biomarker for PMOP. Its elevated expression might participate in osteoporosis progression by regulating osteogenic differentiation.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2677988"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous estetrol/drospirenone regimen for the treatment of endometriosis-related pain: preliminary results.","authors":"Michela Dell'Aquila, Luigi Della Corte, Dimitrios Kafetzis, Giuseppe Bifulco, Costantino Di Carlo, Pierluigi Giampaolino","doi":"10.1080/09513590.2026.2662694","DOIUrl":"10.1080/09513590.2026.2662694","url":null,"abstract":"<p><strong>Purpose: </strong>Endometriosis is a chronic inflammatory condition that causes significant physical and psychological distress. This study aimed to evaluate the therapeutic efficacy and safety of a combined oral contraceptive containing estetrol (E4, 14 mg) and drospirenone (DRSP, 3 mg) in managing endometriosis-related pain.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was carried out at the Endometriosis Center, Federico II University Hospital, Naples, from January 2024 to November 2024. Forty patients with diagnosis of endometriosis and significant pain symptoms (VAS > 6) were included and received E4/DRSP under a continuous regimen for 6 months. Chronic pelvic pain, dyspareunia, dysmenorrhea, and patient quality of life were assessed at baseline, after 3 and 6 months. In the group of patients with endometrioma, reduction in size was evaluated.</p><p><strong>Results: </strong>E4/DRSP significantly reduced chronic pelvic pain and dyspareunia. Dysmenorrhea was resolved entirely due to amenorrhea induction. Endometriomas decreased in size by 30% on average after 6 months. Adverse effects were mild and occurred in 13/40 of patients (32.5%).</p><p><strong>Conclusion: </strong>E4/DRSP demonstrated efficacy and tolerability for managing endometriosis-related pain, offering a promising option for long-term treatment. Further research is needed to confirm its impact on lesion regression and disease progression.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2662694"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone mineral density, body composition, sex hormone levels, and insulin sensitivity in patients with Polyendocrine Metabolic Ovarian Syndrome.","authors":"Caroline P Lopes, Gustavo Ar Maciel, Giovana Dn Maffazioli, Peter Chedraui, Renata Macchione, Erika Mendonça das Neves, José Maria Soares-Jr, Rosa Maria Rodrigues Pereira, Edmund C Baracat","doi":"10.1080/09513590.2026.2732395","DOIUrl":"https://doi.org/10.1080/09513590.2026.2732395","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate bone mineral density (BMD), body composition, sex hormone levels, and insulin sensitivity in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) and compare these parameters with those of women without the syndrome.</p><p><strong>Methods: </strong>This cross-sectional study included 51 women with PMOS diagnosed according to the Rotterdam criteria and 30 women without the syndrome. Clinical characteristics, hormonal and metabolic profiles, body composition, and dual-energy X-ray absorptiometry-derived BMD were assessed. Women with PMOS were also stratified according to the presence or absence of insulin resistance.</p><p><strong>Results: </strong>Women with PMOS exhibited significantly higher BMD at the total body, lumbar spine, femoral neck, and total hip than controls (all <i>p</i> < 0.05). Among women with PMOS, those with insulin resistance had higher femoral neck BMD than those without insulin resistance (1.124 vs. 0.950 g/cm², <i>p</i> = 0.01). This association remained significant after adjustment for body mass index.</p><p><strong>Conclusion: </strong>Women with PMOS had higher BMD across all evaluated skeletal sites than women without the syndrome. Within the PMOS group, insulin resistance was not independently associated with BMD after adjustment for body mass index, indicating that excess body weight may be a more important determinant of bone density than insulin resistance itself.Bone mass in PMOS: new insights into hyperandrogenism and hyperinsulinemia.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2732395"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter-rater reliability and clinical utility of the modified ferriman-gallwey scale in routine practice.","authors":"Irena Chongaroonngamsang, Phawat Matemanosak, Chitkasaem Suwanrath, Krantarat Peeyananjarassri, Noppasin Khwankaew, Alan Geater","doi":"10.1080/09513590.2026.2692736","DOIUrl":"https://doi.org/10.1080/09513590.2026.2692736","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the reliability and clinical utility of the modified Ferriman-Gallwey (mFG) score in routine practice when applied by clinicians with differing experience and by patients for self-assessment.</p><p><strong>Methods: </strong>In this cross-sectional reliability study, 43 reproductive-aged women were assessed for hirsutism. Three clinicians (reproductive endocrinologist, general gynecologist, and resident) independently scored participants using the mFG scale, and patients self-graded their hirsutism. Inter-rater reliability was examined using intraclass correlation coefficients (ICC) and weighted kappa statistics by body area. Clinical agreement was assessed with Bland-Altman limits of agreement (LOA).</p><p><strong>Results: </strong>Inter-rater reliability was good (ICC = 0.649), higher between experienced clinicians (ICC = 0.723) and lower when the resident was included (ICC = 0.588). Weighted kappa ranged from 0.118 to 0.832 (highest for chin, lowest for upper back). Bland-Altman analysis showed substantial disagreement: experienced pair bias -0.74 (LOA -6.94 to + 5.46) and less-experienced pair bias + 0.44 (LOA -7.22 to + 8.11). Patient self-scoring showed poor agreement with clinician scoring (ICC = 0.20).</p><p><strong>Conclusions: </strong>Although clinician scoring demonstrated good statistical reliability, inter-rater differences remained clinically meaningful, with LOA exceeding diagnostic thresholds for hirsutism. Greater experience improved agreement but did not eliminate variability. Patient self-scoring showed low agreement with experts and tended to overestimate severity; however, it may function as a high-sensitivity screening adjunct rather than a substitute for clinician assessment.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2692736"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.","authors":"Nicola Pluchino, Jonas Vibert, Mareike Roth, Ursula Gobrecht, Janna Pape, Susanna Weidlinger, Gabriele Merki-Feld","doi":"10.1080/09513590.2026.2670826","DOIUrl":"https://doi.org/10.1080/09513590.2026.2670826","url":null,"abstract":"<p><strong>Objective: </strong>To review recent evidence on the association between progestin exposure and meningioma risk and to propose practical recommendations for hormonal management in women requiring progestin therapy.</p><p><strong>Methods: </strong>A narrative review of studies published between 2015 and 2025 evaluating the relationship between exogenous progestins and meningioma development, growth, or progression was performed. Evidence regarding different progestin compounds, cumulative exposure, reversibility after discontinuation, and implications for gynecologic practice was analyzed.</p><p><strong>Results: </strong>Meningiomas account for more than one-third of intracranial tumors and occur two to three times more frequently in women, supporting a potential hormonal influence mediated by progesterone receptors, which are expressed in most tumors. The increasing use of MRI has led to more frequent detection of incidental meningiomas in premenopausal women using progestins for contraception or gynecologic conditions such as endometriosis and heavy menstrual bleeding. Consistent associations with increased meningioma risk were observed for high-dose or prolonged exposure to cyproterone acetate, chlormadinone acetate, nomegestrol acetate, and medroxyprogesterone acetate. Risk appeared to increase with cumulative exposure and decrease after treatment discontinuation. Evidence for other progestins, including desogestrel, dienogest, levonorgestrel, and the levonorgestrel-releasing intrauterine system, remains limited and less conclusive.</p><p><strong>Conclusions: </strong>Women's health specialists should systematically assess a history of meningioma before prescribing progestins. In patients with incidental meningioma, discontinuation of high-risk progestins should be considered, followed by MRI reassessment within 3-6 months. When hormonal treatment remains necessary, the lowest effective dose and regular neuro-oncologic monitoring are recommended. Increased awareness and individualized counseling are essential to optimize hormonal management in women at risk of meningioma.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2670826"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.","authors":"Francesco La Torre, Eleonora Nardi, Francesca Bonechi, Silvia Vannuccini, Flavia Sorbi, Massimiliano Fambrini, Francesca Castiglione, Gian Franco Zannoni, Andrea Morandi, Fernando M Reis, Felice Petraglia","doi":"10.1080/09513590.2026.2692730","DOIUrl":"10.1080/09513590.2026.2692730","url":null,"abstract":"<p><strong>Background: </strong>Adenomyosis is a benign uterine disease that has been associated with endometrial proliferative disorders. Adenomyosis and endometrial cancer (EC) are sex-steroid-dependent conditions that may coexist, but their estrogen receptor (ER) and progesterone receptor (PR) signaling landscape is poorly defined.</p><p><strong>Objective: </strong>The present multicenter study aimed to characterize the expression of estrogen <i>(ESR1</i>/<i>ESR2</i> plus the coregulators <i>NCOA1</i>, <i>CCND1</i>, <i>BRCA1</i>) and progesterone (<i>PGR</i> plus <i>FOXO1</i>, and <i>CYP26A1</i>) receptor pathway-related genes in hysterectomy specimens of patients with adenomyosis and coexisting EC.</p><p><strong>Methods: </strong>Specimens from three groups of patients (<i>n</i> = 10 per group) referred to two tertiary hospitals were studied: adenomyosis plus EC (Group 1), only adenomyosis (Group 2), and only EC (Group 3). Gene expression was assessed by droplet digital PCR using a compartment-matched design. Analysis was compartment-specific, and no cross-compartment comparisons were performed.</p><p><strong>Results: </strong>Compared with isolated adenomyosis, adenomyotic lesions from uteri with coexisting EC showed higher <i>ESR2</i> (<i>p</i> = 0.0082) and <i>BRCA1</i> (<i>p</i> = 0.0007) expression, with no differences in <i>ESR1</i>, <i>NCOA1</i>, or <i>CCND1</i>. PR-related gene expression (<i>PGR</i>, <i>FOXO1</i>, and <i>CYP26A1</i>) did not differ between adenomyosis groups.</p><p><strong>Conclusion: </strong>Although preliminary, the present findings indicate that adenomyosis coexisting with EC is characterized by elevated expression of <i>ESR2</i> and <i>BRCA1</i>, suggesting an enriched ER-related microenvironment that may be relevant to local estrogen responsiveness.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2692730"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of NAT10-mediated RNA acetylation in premature ovarian insufficiency: a mechanistic review.","authors":"Yinyan Pan, Yuxia Zhang, Xilong Teng, Yingchun Zhang","doi":"10.1080/09513590.2025.2610551","DOIUrl":"10.1080/09513590.2025.2610551","url":null,"abstract":"<p><p>Premature ovarian insufficiency (POI) is a multifactorial disease characterized by premature depletion of ovarian follicles, leading to impaired ovarian function and increased risk of systemic diseases such as osteoporosis and cardiovascular disease. Although POI significantly impacts women's reproductive health and increases the risk of systemic diseases, little is known about its potential mechanisms, which limits early diagnosis and treatment options. <i>N</i>-acetyltransferase 10 (NAT10), a key regulator of RNA acetylation, plays a crucial role in gene expression, cellular homeostasis, and stress response. This review explores the role of NAT10 in POI, emphasizing its involvement in cell apoptosis, autophagy, ferroptosis, inflammation, oxidative stress, and oocyte maturation disorders. Evidence reveals the dual role of NAT10 in regulating cell damage, balancing protective antioxidant defense and pro-apoptotic/inflammatory pathways depending on the cellular context. Dysregulation of NAT10 suggests its potential utility as a biomarker for early POI diagnosis. Furthermore, NAT10 inhibitors such as Remodelin may reduce ovarian cell damage by modulating apoptosis, inflammation, and oxidative stress. While these findings highlight NAT10 as a promising diagnostic and therapeutic target, challenges remain due to the complexity of its mechanisms and the need for more specific inhibitors. Translating these insights into clinical practice requires integrating molecular and clinical research to refine NAT10-based strategies. This review underscores the pivotal role of NAT10 in the pathophysiology of POI, paving the way for precision medicine and novel therapies targeting NAT10 to address ovarian dysfunction.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2610551"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory markers mediate the association of the Zhejiang University index with gestational diabetes mellitus: data from NHANES 2007-2020.","authors":"Mengmeng Ye, Haochan Wu, Fangfang Shan, Hui Zhou, Jinjin Yu, Yibo Wu, Tingting Hao","doi":"10.1080/09513590.2026.2668870","DOIUrl":"10.1080/09513590.2026.2668870","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) threatens maternal and infant health, yet early prediction is challenging. The Zhejiang University (ZJU) index, reflecting insulin resistance and hepatic lipid metabolism, predicts metabolic diseases, but its role in GDM across multiethnic populations is unclear.</p><p><strong>Methods: </strong>This study analyzed NHANES 2007-2020 data from US women aged 20-45. Weighted logistic regression, restricted cubic spline (RCS), subgroup, and ROC analyses assessed ZJU index and GDM. Mediation analysis evaluated inflammatory ratios. Sensitivity analysis excluded women with chronic diseases or medication use.</p><p><strong>Results: </strong>Among 2240 women, 10% had GDM. Higher ZJU index was linearly associated with increased GDM risk; highest quartile had over twice the odds (OR = 2.25, 95% CI: 1.10-3.41). ZJU index outperformed BMI, FPG, ALT, AST (AUC = 0.718). PHR and LHR partially mediated the association. Sensitivity analysis confirmed robustness.</p><p><strong>Conclusion: </strong>ZJU index is a strong, independent predictor of GDM, outperforming traditional markers. HDL‑related inflammatory markers partially mediate this association, suggesting immunometabolic pathways. Further studies are needed for validation in broader populations.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2668870"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.","authors":"Paul Charles M Piette, James A Simon","doi":"10.1080/09513590.2026.2694742","DOIUrl":"10.1080/09513590.2026.2694742","url":null,"abstract":"<p><strong>Objective: </strong>Identify estradiol serum levels associated with vasomotor symptom relief and assess their effects on osteoporosis and cardiovascular prevention using an estradiol hydro-alcoholic gel formulation.</p><p><strong>Methods: </strong>Estradiol serum concentrations from two pivotal efficacy and safety trials with transdermal (TdL) estradiol gel were compared to those reported in the KEEPS and ELITE trials regarding skeletal and cardiovascular disease prevention.</p><p><strong>Results: </strong>A total of 567 patients were included in the intent-to-treat efficacy population. In the first study (<i>n</i> = 216), the daily 2.5 g dose of TdL E2 gel reduced the moderate to severe hot flash frequency from a baseline of 10.5 to 2.0 ± 4.2 (-82%). In the second study (<i>n</i> = 351), a daily 2.5 g dose of TdL E2 gel reduced moderate-to-severe hot flushes from 11.8 to 2.3 ± 3.8, similar to the TdL E2 patch, which decreased them from 10.9 to 1.3 ± 3.2. The serum concentrations of E2 from patients receiving the TdL E2 gel once daily were within the normal range of young premenopausal women in the mid-follicular phase, with a proportional dose‒response effect.</p><p><strong>Conclusions: </strong>These results on vasomotor symptoms are consistent with the optimal cardiovascular and skeletal benefits observed in KEEPS (TdL estradiol) and ELITE (oral estradiol), corresponding to serum levels of approximately 60 pg/mL.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2694742"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of serum miR-4677-3p combined with ultrasound in endometriosis.","authors":"Jiancai Chen, Xiaojie Shen, Yuanyuan Li, Jingsi Ma, Xiaowei Shen","doi":"10.1080/09513590.2026.2693409","DOIUrl":"https://doi.org/10.1080/09513590.2026.2693409","url":null,"abstract":"<p><strong>Objective: </strong>Endometriosis faces diagnostic delays due to the lack of tools for diagnostic evaluation. The value of miR-4677-3p combined with ultrasound in the diagnosis of endometriosis.</p><p><strong>Methods: </strong>110 healthy subjects and 110 endometriosis patients were recruited. miR-4677-3p level was detected by qRT-PCR. Color Doppler ultrasound was used to measure uterine artery blood flow parameters. Pearson analysis was applied to explore the correlation between miR-4677-3p and blood flow parameters. ROC curve was used to evaluate the diagnostic value. Logistic regression analysis was performed to identify risk factors.</p><p><strong>Results: </strong>miR-4677-3p serum expression in endometriosis patients was upregulated, EDV and PSV were decreased, while PI and RI were increased. miR-4677-3p level was negatively correlated with RI and PI, and positively correlated with EDV and PSV. miR-4677-3p has diagnostic value for endometriosis, with an AUC of 0.863. After combination with ultrasound parameters, the AUC increased to 0.925, indicating a superior diagnostic value for endometriosis. Aberrantly expressed miR-4677-3p, dysmenorrhea, and CA125 as risk factors.</p><p><strong>Conclusion: </strong>The combined application of serum miR-4677-3p and ultrasound parameters can improve the diagnostic efficiency of endometriosis, providing a clinical tool for the accurate identification of the disease.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"42 1","pages":"2693409"},"PeriodicalIF":3.0,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}